Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MANDARA study of benralizumab versus mepolizumab in eosinophilic granulomatosis with polyangiitis
2023-510248-19-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic granulomatosis with polyangiitis (EGPA) comparing Benralizumab arm with Mepolizumab active control arm (2 arms). Planned start Jan 2020; status: authorised.
02
Drugs
benralizumabmepolizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on 2023-510248-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510248-19-00.